Rapid Pathogen Screening, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 489 | 99.8% |
| Food and Beverage | $2,989 | 269 | 0.2% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| FebriDx | $790,289 | 1 | 64 |
| FebriDx DISRUPT | $366,683 | 0 | 33 |
| Blitz | $176,470 | 0 | 7 |
| CoviDx | $110,069 | 0 | 4 |
| CoviDx OTC | $34,460 | 0 | 1 |
| CoviDxPOC | $7,290 | 0 | 2 |
| RPS-AP | $1,163 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 13
Top Products
- FebriDx $718,534
- FebriDx DISRUPT $366,683
Associated Products (5)
- FebriDx $737,073
- FebriDx DISRUPT $366,683
- Blitz $176,470
- CoviDx $110,069
- CoviDx OTC $34,460
Payment Categories
- Food & Beverage $2,989
- Research $1.5M
About Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. has made $1.5M in payments to 321 healthcare providers, recorded across 758 transactions in the CMS Open Payments database. In 2022, the company paid $56,359. The top product by payment volume is FebriDx ($718,534).
Payments were distributed across 33 medical specialties. The top specialty by payment amount is Infectious Disease ($5,650 to 1 doctors).
Payment categories include: Food & Beverage ($2,989), Research ($1.5M).
Rapid Pathogen Screening, Inc. is associated with 5 products in the CMS Open Payments database, including FebriDx, FebriDx DISRUPT, and Blitz.